A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it.
The study will last approximately 10 weeks excluding a screening period.